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ABSTRACT: Object ive: The purpose of this study
was to examine the relationship between vascular dis-
ease (and vascular risk factors), cognition and motor
phenotype in Parkinson’s disease (PD).
Methods: Recently diagnosed PD cases were enrolled in
a multicenter prospective observational longitudinal cohort
study. Montreal cognitive assessment (normal >23, mild
cognitive impairment 22 to 23 or lower but without func-
tional impairment, and dementia 21 or less with functional
impairment) and Movement Disorder Society Unified PD
Rating Scale part 3 (UPDRS 3) scores were analyzed in rela-
tion to a history of vascular events and risk factors.
Results : In 1759 PD cases, mean age 67.5 (standard
deviation 9.3) years, mean disease duration 1.3 (standard
deviation 0.9) years, 65.2% were men, 4.7% had a history of
prior stroke or transient ischemic attack, and 12.5% had car-
diac disease (angina, myocardial infarction, heart failure). In
cases without a history of vascular disease, hypertension
was recorded in 30.4%, high cholesterol 27.3%, obesity
20.7%, diabetes 7.2%, and cigarette smoking in 4.6%.
Patients with prior stroke or transient ischemic attack were
more likely to have cognitive impairment (42% vs 25%) and
postural instability gait difficulty (53.5% vs 39.5%), but these
findings were not significant after adjustment for age, sex,
and disease duration (P5 .075). The presence of more than
2 vascular risks was associated with worse UPDRS 3 motor
scores (beta coefficient 4.05, 95% confidence interval 1.48,
6.61, p 5 .002) and with cognitive impairment (ordinal odds
ratio 2.24, 95% confidence interval 1.34, 3.74, p 5 .002). In
842 patients (47.8%) with structural brain imaging, white
matter leukoaraiosis, but not lacunar or territorial infarction,
was associated with impaired cognition (p5 .006) and pos-
tural instability gait difficulty (p5 .010).
Conclusion: Vascular comorbidity is significantly associ-
ated with cognitive and gait impairment in patients with
early PD, which may have prognostic and treatment
implications. VC 2016 The Authors. Movement Disorders
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Cognitive impairment and dementia are recognized
consequences of the evolving neurodegenerative proc-
esses underlying Parkinson’s disease (PD) and represent
a significant management issue. Impaired cognition is
increasingly recognized in early PD, graded as mild cog-
nitive impairment in 14.2% and dementia in 16.3% of
cases in one study (N 5 492) within 3.5 years of diag-
nosis.1 In another study that excluded cases with
dementia, 34% had mild cognitive impairment (MCI)
at an average patient age of 61 years and a mean dis-
ease duration of 3.4 years at the time of their first
assessment.2 However, cognitive impairment and
dementia in PD may also relate to comorbid cerebro-
vascular disease. Clinical, imaging, and pathological
studies highlight the adverse impact of cerebrovascular
disease and vascular risk factors including diabetes,
hypertension, and dyslipidemia on cognition and motor
tasks (particularly gait).3-6 Because the prevalence of
cerebrovascular disease and vascular risk factors
increases with age, particularly in high-income coun-
tries, it seems likely that they contribute to cognitive
impairment and motor disability in PD.
Gait impairment and falls result, in part, from motor
dysfunction in PD and are more likely in patients with
axial involvement, recognized clinically as the postural
instability gait difficulty (PIGD) motor phenotype, dis-
tinct from the tremor dominant (TD) motor pheno-
type.7 An association of the PIGD phenotype with
cognitive impairment is well documented in PD,8 and
gait impairment is common after ischemic stroke but
also occurs in the absence of acute cerebrovascular
events.9,10 Specifically, in PD, subclinical cerebrovascu-
lar disease was linked to greater motor severity and
increased gait impairment in two small, but detailed,
studies that included structural MRI and functional
dopaminergic imaging.11,12 Axial impairment increased
in relation to the white matter cerebrovascular burden
with a stronger relationship than that between white
matter changes and bradykinesia, and there was no
relationship with either tremor or rigidity.12 An overlap
syndrome between PD and cerebrovascular disease may
therefore create a mixed motor phenotype and explain
the limited responsiveness of some of these motor and
cognitive features to antiparkinsonian therapy.
Because some of these risk factors are modifiable,13
reducing the direct effects of ischemia-related neuronal
loss would be one aim of this approach to limit the
damaging effects from comorbid cerebrovascular dis-
ease on cognition and gait. Progression of such cogni-
tive and gait problems in PD occurs on average at 6.2
years from diagnosis to dementia and 7.1 years from
diagnosis to falls in prospective studies.14,15 A window
of opportunity may therefore exist around the time of
diagnosis of PD, or earlier, considering current research
efforts in identifying premotor or preclinical PD.
Although there are wider population-based initiatives
looking at preventive approaches for vascular disease to
reduce vascular dementia rates, the issues in PD may be
even more pertinent. More specific interaction between
vascular risk factors and PD have been proposed that
involve acceleration of the neurodegenerative process,
particularly in the presence of diabetes.16
Our objective was to test the hypothesis that vascu-
lar and metabolic factors are associated with cognitive
and motor features in recent onset PD, with the aim
of explaining differences in PD phenotype that arise
from these comorbidities.
Methods
Tracking Parkinson’s study is a large, prospective,
observational, multicenter project in the United King-
dom. Patients were recruited with a clinical diagnosis
of PD, fulfilling Queen Square Brain Bank criteria17
and supported by structural and/or functional neuroi-
maging performed when the diagnosis was not firmly
established clinically. Both drug-na€ıve and -treated
patients aged 18 to 90 years were eligible. All cases
were diagnosed with PD in the preceding 3.5 years,
and recruitment was completed between February 2012
and May 2014. Patients were excluded in the presence
of severe comorbid illness, other degenerative forms of
parkinsonism (eg, progressive supranuclear palsy), or
symmetrical lower body parkinsonism attributable to
significant cerebrovascular disease (patients with inci-
dental vascular disease on brain imaging were not
excluded). Patients with drug-induced parkinsonism
were excluded, but drug-unmasked PD was allowed if
justified by abnormal functional dopaminergic imaging.
Patients with a clinical diagnosis of dementia at their
first assessment were also excluded. Patients were
enrolled in a 6-month follow-up, but only results from
the baseline visit are reported in this article. Enrolled
patients whose diagnosis was later changed, on clinical
or imaging grounds, were excluded from the analysis.
In addition, patients with missing data or in whom
there were atypical features that might indicate an
alternative diagnosis, including those with a minimal
response to dopaminergic therapy, were excluded from
the main analysis.
The study was carried out in accordance with the
Declaration of Helsinki. Research funding for this pro-
ject is from Parkinson’s UK, the national patient care
and research organization.
A total of 72 sites in the United Kingdom providing
secondary care treatment for PD patients as part of
the UK National Health Service (and in selected sites,
their linked academic institutions) participated, with
multicenter ethics committee and local research and
development department approvals. All participating
patients provided written informed consent at the time
of recruitment.
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Clinical assessments were made at baseline using
standardized and validated scales to document the
motor and nonmotor features and quality of life of the
enrolled patients. Levodopa equivalent daily dose was
calculated using established formulae for dose equiva-
lence.18 Motor subtypes were determined using the
Movement Disorder Society Unified Parkinson’s Disease
Rating Scale part 3 (UPDRS 3) scores using a predeter-
mined formula.7 Motor scoring was performed without
stopping antiparkinsonian medication, and the motor
state was recorded as either being “on” or “off”
(although such fluctuations are rare at this stage of dis-
ease). Montreal cognitive assessment (MoCA) scores
were adjusted for years of education. Predetermined
diagnostic cut-offs were used to categorize cases into
normal (>23) mild cognitive impairment (MCI) 22-23
or less than 22 but without functional impairment and
dementia (21 or less with functional impairment) to
reflect core criteria for PD dementia defined by the
Movement Disorder Society Task Force.19
Prior medical histories were recorded by the patients,
often with corroboration from a spouse or caregiver,
including previous histories of stroke, transient ischemic
attack (TIA), or cardiac disease (angina, myocardial
infarction, or heart failure). Neuroimaging was per-
formed on clinical grounds (1.5 or 3T), and findings
were categorized by visual reporting as revealing lacu-
nar or territorial infarction and/or periventricular/sub-
cortical white matter hyperintensities (leukoaraiosis).
For overall assessment of vascular disease risk, we cal-
culated QRISK2, which encompasses risk factors
including age, gender, elevated cholesterol, blood pres-
sure/treatment, diabetes, smoking status, body mass
index, and chronic kidney disease and is appropriate in
patients who have not had a prior vascular event.20
Furthermore, we searched PubMed and the Cochrane
Database up to November 1, 2015, combining the
search terms “vascular,” “leukoaraiosis,” “diabetes,”
“hypertension,” “stroke,” and “Parkinson’s” to look
for any other similar studies so that our research could
be put into context and our results compared with
other studies.
Statistical Analysis
The main analysis was performed without imputa-
tion of missing data in the 1759 patients with avail-
able data and without atypical features. Additional
analyses were undertaken in 2 ways.
First, imputation was performed with the main data
set (N 5 1759). We used imputation methods to adjust
for missing outcomes and exposure data. For MoCA,
motor phenotype, and UPDRS 3, we first calculated
expected scores where at least 80% of the responses
were available by up-weighting the score based on
answered questions (eg, when 30 of 33 questions were
answered, the score was uprated by multiplying by 33/
30). Any remaining missing data were imputed using
the chained equation approach to multiple imputation,
creating 10 imputed data sets. MoCA scores and
UPDRS scores were imputed using predictive mean
matching and motor phenotype using multinomial
logistic regression. Estimates and P values were derived
from the 10 datasets using Rubin’s rules.21
Second, analyses were performed without imputa-
tion (n 5 1930). We applied the methodology used
for data analysis in the main dataset (n 5 1759) to
the bigger dataset (ie, including cases with one or
more atypical features).
Phenotypic characteristics requiring covariate adjust-
ment were analyzed using multivariable regression.
For UPDRS 3 scores, standard linear regression was
used for categorized MoCA ordered logistic regression
(also called a proportional odds model) and for motor
phenotype multinomial logistic regression with tremor
dominant as the baseline. We adjusted for levodopa
equivalent daily dose in our models using UPDRS 3 as
the dependent variable and for drug naivete in the
analyses for cognitive impairment. For analysis of the
association between categorized neuroimaging results
and the different outcomes, heterogeneity P values
across the three groups were calculated (ie, a hypothe-
sis test that all three groups are equivalent with
regards to the outcome). All P values were 2-tailed; P
values were calculated before and after adjustment for
potential confounders. Statistical analysis was con-
ducted using STATA (version 13, StataCorp, College
Station, Texas).
Results
There were 2006 patients recruited, of whom 247
(12.3%) were excluded for the following reasons:
change in diagnosis (during a mean follow-up from
baseline of 2.6 years, SD 0.6); protocol violation; miss-
ing data (which affected 6.7% to 8.0% for outcomes,
but taking into account those who answered at least
80% of the questions it ranged from 0.3% to 2.8%);
or possible atypical features raising diagnostic doubt
(Fig. 1). The main analysis group therefore consisted of
1759 PD cases, mean age was 67.5 (SD 9.3) years,
mean disease duration 1.3 (SD 0.9) years, and 65.2%
were male (Table 1). Of the patients, 4.7% had a prior
history of stroke or TIA, and 12.5% had cardiac dis-
ease (angina, myocardial infarction, heart failure; Table
2). Vascular risk factors (in those without a history of
stroke, TIA, or cardiac disease) were hypertension
30.4%, high cholesterol 27.3%, obesity 20.7%, diabe-
tes 7.2%, and cigarette smoking 4.6%. With regard to
the exposures, missing data were less than 2.5% for all
variables except smoking that had 12.4% missing data.
Diabetes was significantly associated with increased
motor severity (P 5 .006). Those with diabetes had a
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UPDRS 3 score that was approximately 3.7 points
higher (95% confidence interval [CI] 1.07, 6.22) than
those without diabetes (Table 3). There was no associ-
ation between diabetes and PIGD (data not shown).
The presence of multiple (>2) vascular risk factors
was also significantly associated with UPDRS 3 scores
(P 5 .002; Table 3). QRISK2 score >20 was associ-
ated with higher UPDRS 3 scores (P < .001; Table 3),
further confirming this association between vascular
risk factors and motor severity. Our sensitivity analy-
sis excluding drug na€ıve patients found very similar
associations (results not shown).
Cases with more than 2 vascular risk factors were
significantly more likely to have cognitive impairment
(P 5 .002; Table 4).
Structural brain imaging was performed in 842 cases
(47.9% of 1759 cases; Table 5). Cognitive impairment
was more common in patients with white matter leu-
koaraiosis, in whom any degree of cognitive impair-
ment was recorded in 44.6%, versus 23.7% in those
with lacunar or territorial infarcts and 22.9% in those
with no vascular disease on imaging (P 5 .006). The
odds ratio for cognitive impairment for those with leu-
koaraiosis only compared with those with no vascular
disease on imaging was 1.88, 95% CI 1.21, 2.91.
Furthermore, more cases with the PIGD motor phe-
notype (61.4%) were seen in those with leukoaraiosis
than those with either lacunar or territorial stroke
(39.1%) or no vascular disease on imaging (42.8%; P
5 .01). The odds ratio for PIGD for those with leu-
koaraiosis only compared with those with no vascular
disease on imaging was 1.81, 95% CI 1.14, 2.88
(Table 5).
Analysis of the relationships between vascular dis-
ease and risk factors, and motor and cognitive severity
and pattern, in the 1759 patients after multiple impu-
tation showed some differences from the nonimputed
datasets (Supporting Information Tables 1 to 4). The
association between PIGD motor phenotype and his-
tory of stroke was significant (P 5 .018) and also
between UPDRS 3 and history of cardiac disease (P 5
.034). The association between number of vascular
risk factors and UPDRS 3 was now significant for 1 (P
5 .049) and 2 (P 5 .030) vascular risk factors, and
remained significant for >2 risk factors (P < .001).
All other significant associations seen in the nonim-
puted dataset remained significant after data imputa-
tion. In an analysis of the 1930 cases (ie, including
those with one or more atypical features), associations
were almost identical to those in the main analysis,
but there was an additional significant association
between diabetes and cognitive impairment (odds ratio
1.90, CI 1.16, 3.11, P 5 .011), which was not found
in either the main or the imputed analyses. Similar to
the imputed analysis, we also found a significant asso-
ciation between obesity and UPDRS 3 (P 5 .031).
Discussion
The association of vascular risk factors and the phe-
notypic expression of PD has until now been the
TABLE 1. Demographic and motor profile in 1759 cases of
recent onset PD and no unusual presentation features
Characteristic
Total
N (%) or mean (SD)
Age in years Onset/Diagnosis/
At baseline
64.3 (9.8)/66.1(9.3)/
67.5 (9.3)
Gender (male) 1147 (65.2)
Disease duration
in years
1.3 (0.9)
Race, White 1720 (98.2)
Symptoms at onset Tremor/Rigidity/
Bradykinesia/
Postural instability
1304 (75.6)/1181 (71.9)/
1309 (78.0)/306 (18.8)
Motor subtype TD/PIGD/
Indeterminate
765 (47.0)/653 (40.1)/
209 (12.9)
UPDRS 3 22.5 (12.1)
Hoehn and
Yahr stage
0/1/2/3/4/5 5 (0.3)/863 (49.7)/
767 (44.2)/
97 (5.6)/4 (0.2)/1 (0.1)
Drug na€ıve 172 (9.8)
LEDD (mg/day) 293 (205)
PD, Parkinson’s disease; SD, standard deviation; TD, tremor dominant;
PIGD, postural instability gait difficulty; UPDRS 3, Movement Disorder Soci-
ety Unified Parkinson’s Disease Rating Scale Part 3; LEDD, levodopa
equivalent daily dose.
FIG. 1. CONSORT flow diagram showing the disposition of cases
recruited to the study and reasons for exclusion from the main analy-
sis dataset of 1759 patients. Additional analyses were undertaken
using multiple imputations for missing data in the 1759 cases and on
the full dataset of 1930 cases with available data (see text).
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subject of few studies and then only involving small
patient numbers.11,12 Cerebrovascular disease (macro-
scopic infarcts, micro-infarcts, and arteriolosclerosis)
is common in the pathogenesis of mild parkinsonian
signs, especially parkinsonian gait, particularly in the
elderly.22 Furthermore, there is a significant associa-
tion between impaired cognition and cerebrovascular
disease.23 Finally, both cerebrovascular disease and
PD are predictors for the development of the motoric
cognitive risk syndrome, a newly described predemen-
tia syndrome characterized by slow gait and cognitive
complaints.24,25 In this large prospective longitudinal
study of patients with recent onset PD, we found that
cognitive impairment was more prevalent in those
with multiple vascular risk factors. There are observa-
tions of cognitive impairment and dementia in diabetic
TABLE 3. Motor severity in recent onset PD, in relation to vascular risk factors, restricted to 1483 cases without a history
of stroke, TIA, or cardiac disease
UPDRS 3a
Number (%) Mean (SD) Betab (95% CI) P value
Vascular risk factors
Cigarette smoking 60 (4.6) 22.5 (14.8) 2.20 (20.88, 5.28) .16c
Hypertension 449 (30.4) 23.7 (11.9) 0.97 (20.57, 2.51) .22c
High cholesterol 404 (27.3) 23.0 (12.1) 20.38 (21.96, 1.20) .64c
Diabetes mellitus 106 (7.2) 27.3 (14.8) 3.65 (1.07, 6.22) .006c
BMI > 30 300 (20.7) 23.4 (11.7) 1.58 (20.06, 3.22) .060c
Number of vascular risk factorsd
None 568 (44.2) 20.2 (10.7) 0 (ref) .12
1 409 (31.9) 21.8 (12.5) 1.20 (20.32, 2.72) .29
2 213 (16.6) 22.0 (11.7) 1.01 (20.87, 2.90) .002
>2 94 (7.3) 25.2 (11.1) 4.05 (1.48, 6.61)
Vascular risk score, QRISK2 > 20 552 (37.6) 24.6 (12.6) 3.41 (1.62, 5.20) <.001
PD, Parkinson’s disease; TIA, transient ischemic attack; UPDRS 3, Movement Disorder Society Unified PD Rating Scale Part 3; SD, standard deviation; CI,
confidence interval; BMI, body mass index.
aLinear regression model, UPDRS score for all patients was mean 21.9 (SD 11.9)
bAdjusted for age, gender, disease duration, and levodopa equivalent daily dose; result is from comparison of cases with vascular risk to those without.
cAlso mutually adjusted for all vascular risk factors.
dRestricted to complete cases and formal test of linear trend versus heterogeneity gave P value of .36 (unadjusted analysis).
TABLE 2. Motor and cognitive profile classified by prior history of stroke or cardiac disease, in cases with no unusual pre-
sentation features
Previous stroke
or TIA, N (%)
Model estimatesd
(95% CI) p valued
Cardiac disease,
N (%)
Model estimatesd
(95% CI) P valuedCharacteristic Yes No Yes No
83 (4.7) 1674 (95.3) 218 (12.5) 1532 (87.5)
Montreal cognitive assessmenta
Normal 47 (58.0) 1170 (75.0) 1.53e (0.96, 2.45) 0.075f 132 (63.2) 1080 (75.7) 1.22e (0.89, 1.68) .22f
MCI 31 (38.3) 349 (22.4) 67 (32.1) 313 (21.9)
Dementia 3 (3.7) 40 (2.6) 10 (4.8) 33 (2.3)
UPDRS 3b 25.5 (12.0) 22.3 (12.1) 1.37g (21.45, 4.20) 0.34h 25.4 (12.8) 22.1 (11.9) 1.78g (20.04, 3.60) .055h
Motor phenotypec
TD 25 (35.2) 739 (47.5) 1i (ref) 75 (38.3) 687 (48.2) 1i (ref)
PIGD 38 (53.5) 615 (39.5) 1.61i (0.95, 2.72) 0.075 94 (48.0) 555 (39.0) 1.37i (0.98, 1.92) .065
Indeterminate 8 (11.3) 201 (12.9) 1.19i (0.52, 2.69) 0.68 27 (13.8) 182 (12.8) 1.41i (0.87, 2.29) .17
TIA, transient ischemic attack; CI, confidence interval; MCI, mild cognitive impairment; UPDRS 3, Movement Disorder Society Unified Parkinson’s Disease Rat-
ing Scale Part 3; TD, tremor dominant; PIGD, postural instability gait difficulty.
aOrdinal logistic regression model (normal 5 0, MCI 5 1, dementia 5 2).
bLinear regression model.
cMultinomial logistic regression model with TD as baseline.
dAdjusted for age, gender, and disease duration.
eOdds ratio.
fAlso adjusted for drug na€ıve.
gBeta coefficient (adjusted difference in means).
hAlso adjusted for levodopa equivalent daily dose.
iMultinomial odds ratio.
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patients in the general population, with emerging evi-
dence that interactions between several vascular risk
factors are linked to target organ damage.3,11,26-28
Cerebrovascular disease can have a role in modify-
ing the phenotype and progression of PD. Vascular
pathology in PD includes fragmentation of capillaries
and damage to the capillary network in multiple brain
regions, but particularly in the substantia nigra, mid-
dle frontal cortex, and brain stem nuclei. Thus, treat-
ments that prevent vascular degeneration may improve
vascular remodelling in the brain and provide a novel
target to ameliorate the disease burden in PD.29
The presence of leukoaraiosis on structural brain
imaging in the present study was associated with sig-
nificantly greater baseline prevalence of cognitive
impairment than was seen when imaging showed
TABLE 4. Cognitive status in recent onset PD, in relation to vascular risk factors, restricted to 1483 cases without a history
of stroke, TIA, or cardiac disease.
Cognitive statusa
Normal, N (%) MCI, N (%) Dementia, N (%) ORb
(95% CI)Total 1052 (76.4) 294 (21.4) 31 (2.3) P value
Vascular risk factors
Cigarette smoking 45 (78.9) 12 (21.1) 0 (0.0) 1.58 (0.79, 3.13) .19c
Hypertension 302 (71.7) 108 (25.7) 11 (2.6) 1.01 (0.72, 1.40) .97c
High cholesterol 258 (69.7) 103 (27.8) 9 (2.4) 1.30 (0.94, 1.81) .12c
Diabetes mellitus 58 (61.7) 27 (28.7) 9 (9.6) 1.52 (0.89, 2.58) .12c
BMI > 30 209 (74.9) 60 (21.5) 10 (3.6) 1.26 (0.88, 1.81) .22c
Number of vascular risk factorsd
None 437 (82.5) 88 (16.6) 5 (0.9) 1 (ref) .31
1 296 (78.3) 74 (19.6) 8 (2.1) 1.19 (0.85, 1.68) .46
2 155 (76.7) 44 (21.8) 3 (1.5) 1.16 (0.77, 1.75) .002
>2 54 (64.3) 28 (33.3) 2 (2.4) 2.24 (1.34, 3.74)
Vascular risk score, QRISK2 >20 334 (65.1) 159 (31.0) 20 (3.9) 1.43 (0.98, 2.08) .064
PD, Parkinson’s disease; TIA, transient ischemic attack; MCI, mild cognitive impairment; OR, odds ratio; CI, confidence interval; BMI, body mass index.
aOrdinal logistic regression model.
bAdjusted for age, gender, disease duration, and drug na€ıve.
cAlso mutually adjusted for all vascular risk factors.
dRestricted to complete cases.
TABLE 5. Cognitive and motor severity in 842 cases with structural brain imaging
Characteristic
Leukoaraiosis only,
N (%)
Brain CT or MR result
Lacunar or territory
infarct, N (%)
No vascular
disease, N (%)
Model estimated
Leukoaraiosis only
versus no vascular
disease (95% CI)
Model estimated
Lacunar or territory
infarct vs no vascular
disease (95% CI) P valued,e
Total 121 (14.4) 100 (11.9) 621 (73.8)
Montreal cognitive assessmenta
Normal 61 (55.5) 71 (76.3) 447 (77.1) 1.88f (1.21, 2.91) 0.78f (0.46, 1.33) .006g
MCI 39 (35.5) 21 (22.6) 116 (20.0)
Dementia 10 (9.1) 1 (1.1) 17 (2.9)
UPDRS 3b 23.9 (11.3) 23.7 (12.4) 21.4 (11.4) 1.31h (-1.09,3.71) 1.74h (-0.88, 4.36) .30i
Motor phenotypec
TD 33 (28.9) 43 (49.4) 249 (43.2) 1j (ref) 1j (ref)
PIGD 70 (61.4) 34 (39.1) 247 (42.8) 1.81j (1.14, 2.88) 0.72j (0.44, 1.18) .010
Indeterminate 11 (9.6) 10 (11.5) 81 (14.0) 0.88j (0.42, 1.86) 0.65j (0.31, 1.37) .53
Results based on analysis where individuals with unusual presentation were not included.
CT, computed tomography; MR, magnetic resonance; CI, confidence interval; MCI, mild cognitive impairment; UPDRS 3, Movement Disorder Society Unified
PD Rating Scale; TD, tremor dominant; PIGD, postural instability gait difficulty.
aOrdinal logistic regression model (normal 5 0, MCI 5 1, dementia 5 2).
bLinear regression model.
cMultinomial logistic regression model with TD as baseline.
dAdjusted for age, gender, and disease duration.
eHeterogeneity test P value across the three groups.
fOdds ratio.
gAlso adjusted for drug na€ıve.
hBeta coefficient (adjusted difference in means).
iAlso adjusted for levodopa equivalent daily dose.
jMultinomial odds ratio.
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lacunar or territorial infarction or normal brain imag-
ing results. Perhaps an explanation for this could be
that not all acute infarcts affect areas of the brain sub-
serving major cognitive functions. On the other hand,
the burden of leukoaraiosis (or the equivalent descrip-
tions of white matter change/MRI T2 hyperintensity) as
seen on brain imaging relates generally to impaired cog-
nitive performance in the nondisabled elderly as well as
more specifically in PD. These 2 findings are consistent
with each other but neither explains the other.
Although leukoaraiosis is often a marker of small vessel
cerebrovascular disease, other pathological processes
such as inflammation may cause a similar appearance
and could offer an alternative explanation to our find-
ings.3,12,30,31 An earlier detailed review of literature in
this area summarized the findings of 11 studies; 8 of
these described a significant association between leu-
koaraiosis and impaired cognition in PD, but 3 found
no such association.32 Furthermore, although vascular
disease and vascular risk factors may be linked to
impaired cognition in PD, all persons with vascular risk
factors are not cognitively impaired. In our study,
64.3% of the patients with >2 vascular risk factors
had normal cognitive status. In keeping with those
prior studies,33-38 we used predefined cut-offs for the
definition of cognitive state but included a requirement
for impairment of function to define dementia as
required by core criteria of the Movement Disorder
Society Task Force.19
Our search of the literature did not find any large-
scale studies (n > 400) that specifically evaluated the
association of vascular disease (and vascular risk fac-
tors) with motor features and cognition in early PD.
Previous studies have shown that vascular risk factors
and cerebrovascular disease are common in PD
patients, possibly because of their older age. A study
involving 148 patients with PD at about 6 years disease
duration (of whom 15 had diabetes) found that diabe-
tes mellitus was independently associated with more
severe cognitive impairment in PD, likely through
mechanisms other than disease-specific neurodegenera-
tion.39 Another study involving 62 patients suggested
that the severity of leukoaraiosis on MRI imaging is
significantly associated with UPDRS total scores and
motor scores.40 This argument was substantiated in
another critical review that concluded that white matter
leukoaraiosis was associated with worsening axial
motor performance, independent of the degree of nigro-
striatal dopaminergic denervation.41 These small studies
suggest that comorbid cerebrovascular disease and asso-
ciated vascular risk factors can be linked to the pheno-
type of PD but have not defined the prevalence or
severity of such problems in early PD.
Motor severity was greater in our PD patients in the
presence of diabetes, which has also been reported in
a case-control study in recent onset PD.42 Leukoaraio-
sis on imaging was associated with the PIGD motor
phenotype, which is consistent both with the previous
observations relating such imaging changes to posture
and gait problems in the general population and with
prior clinical-imaging studies in PD.9,10,12,31 However,
we did not find an association between the presence of
diabetes and the PIGD phenotype unlike a prior
report.11 Our study is much larger than this other
report, which included only 13 patients with PD and
diabetes, and our cases were also seen much earlier in
their disease course (1.3 years into their illness vs 6.9
years on average). The known evolution of the tremor
dominant motor phenotype toward PIGD in PD8 may
explain this and will be tested in our cohort with fur-
ther follow-up.
There are certain limitations to our study design. The
hospital-based setting of our study may have resulted in
selection bias for structural brain imaging based on
clinical decisions, which is likely to overestimate the
general prevalence of cerebrovascular disease in patients
with PD. On the other hand, patients with major
comorbidities were ineligible for study entry, which
may result in the underrepresentation of significant
comorbid vascular disease. Multiple statistical tests
were performed, and no adjustment was made to the
significance levels to account for this. We had some
missing data that might affect the validity of the results
given that we applied an 80% threshold. However, sen-
sitivity analysis of imputed data confirmed the findings
in the primary analysis, and if we apply a 90% thresh-
old, rates of missing data were also low: MoCA 1.4%,
UPDRS 3 1.0%, and motor phenotype 4.5%.
The diagnosis of PD in our cohort was primarily
clinical, which is subject to known error rates even
when applying specific diagnostic criteria, especially in
early disease.17 However, structural imaging was
applied in 842 cases (47.9%) and functional dopami-
nergic imaging largely in cases of clinical diagnostic
uncertainty (440 cases, 25.0%). In addition, cases
receiving an alternative diagnosis during follow-up
and cases with one or more features that might indi-
cate an alternative diagnosis were also excluded from
the main analysis. The structural brain imaging proto-
cols varied according to site, and analysis was by vis-
ual assessment. Quantitative methods and additional
imaging modalities, such as ultrasound,43 may have
provided more detail but were beyond the scope of
this study. Although we cannot exclude the possibility
that some of our cases may evolve to an alternative
diagnosis, our cohort is representative of what is clini-
cally diagnosed and managed as early PD. The
response to dopaminergic treatment was recorded pro-
spectively in the study, and little or no response to
such treatment was one of the factors used to exclude
cases from the current analysis to define a levodopa-
responsive PD patient cohort. Additional analysis
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performed in the larger patient group, including those
with atypical features, replicated the significant associ-
ations seen in the main, more diagnostically definite
analysis group. Our findings are therefore relevant to
clinical practice and to research studies including early
treatment trials that generally enroll similar popula-
tion cohorts from clinical settings.
We obtained UPDRS motor scores during routine
clinic visits without stopping antiparkinsonian medica-
tion, which may result in a mixture of “on” and “off”
state scorings, although at this early stage of disease
these on-off effects are seldom significant or even evi-
dent. Of the 1624 (of 1759) for whom this was
recorded, only 130 were in the “off” state, of which
44 were not on medication. Hence, this issue affected
only a small proportion (5.3%) of individuals. On-off
state therefore could not have biased our results to
any major degree.
We do plan to collect motor scores during a practi-
cally defined “off” state at a disease duration of 3.5
years or longer. This will add quantitative information
on treatment responsiveness in future reports from this
study.
Disease heterogeneity is well recognized in PD and
is increasingly considered as a factor in the design,
conduct, and interpretation of interventional research
studies.44 We found significant age differences and an
association of vascular comorbidity with the pheno-
typic expression of PD, which exemplify these prob-
lems and have implications for therapeutic trials.
These observations collectively suggest that clinical tri-
als should include an assessment of vascular risk to
balance treatment groups taking account of the pres-
ence of vascular factors and to stratify subgroups
because outcome measures associated with vascular
risk may not be improved by any Parkinson’s disease
modifying effect.44 The mechanistic linkage of vascu-
lar problems with 2 adverse outcomes, cognitive and
gait impairments, which are resistant to standard anti-
parkinsonian treatments, deserve further study.
Future trials to manage vascular and metabolic risk
factors more aggressively deserve consideration
because they may have an additional benefit on PD
disease progression over and above any cardiovascular
benefits.
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